[1]罗贤云.阿托伐他汀联合双抗治疗对急性缺血性脑卒中患者血脂、神经功能及预后的影响[J].医学信息,2022,35(23):133-135,139.[doi:10.3969/j.issn.1006-1959.2022.23.027]
　LUO Xian-yun.Effect of Atorvastatin Combined with Double Antibody Therapy on Blood Lipid, Neurological Function and Prognosis in Patients with Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(23):133-135,139.[doi:10.3969/j.issn.1006-1959.2022.23.027]
点击复制

阿托伐他汀联合双抗治疗对急性缺血性脑卒中患者血脂、神经功能及预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
133-135,139
栏目:
药物与临床
出版日期:
2022-12-01

文章信息/Info

Title:
Effect of Atorvastatin Combined with Double Antibody Therapy on Blood Lipid, Neurological Function and Prognosis in Patients with Acute Ischemic Stroke
文章编号:
1006-1959（2022）23-0133-04
作者:
罗贤云
（上饶市广丰区人民医院急诊科，江西 上饶 334600）
Author(s):
LUO Xian-yun
(Department of Emergency,Guangfeng District People’s Hospital,Shangrao 334600,Jiangxi,China)
关键词:
阿托伐他汀; 急性缺血性脑卒中; 神经功能
Keywords:
Atorvastatin; Acute ischemic stroke; Neurological function
分类号:
R743.31
DOI:
10.3969/j.issn.1006-1959.2022.23.027
文献标志码:
A
摘要:
目的 观察阿托伐他汀联合双抗治疗对急性缺血性脑卒中患者血脂、神经功能及预后的影响。方法 选取2020年6月-2021年6月我院诊治的68例急性缺血性脑卒中患者为研究对象，采用随机数字表法分为对照组和观察组，各34例。对照组采用氯吡格雷联合阿司匹林双抗治疗，观察组在对照组基础上联合阿托伐他汀治疗，比较两组神经功能缺损程度、日常生活能力、凝血功能指标[血酶原时间（PT）、活化部分凝血酶原时间（APTT）、纤维蛋白原（Fg）]、血脂指标[胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）]、不良反应发生率、预后情况。结果 两组治疗后NIHSS评分低于治疗前，Barthel评分高于治疗前，且观察组NIHSS评分低于对照组，Barthel评分高于对照组（P＜0.05）；两组治疗后PT、APTT大于治疗前，Fg小于治疗前，且观察组PT、APTT大于对照组，Fg小于对照组（P＜0.05）；两组治疗后TC、LDL-C低于治疗前，HDL-C高于治疗前，且观察组TC、LDL-C低于对照组，HDL-C高于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）；观察组复发率、出血率均低于对照组（P＜0.05）。结论 阿托伐他汀联合双抗治疗对急性缺血性脑卒中患者血脂、神经功能及预后均具有积极的影响，且不增加不良反应发生几率，是一种安全、有效的治疗方案。
Abstract:
Objective To observe the effect of atorvastatin combined with dual antiplatelet therapy on blood lipid, neurological function and prognosis in patients with acute ischemic stroke.Methods A total of 68 patients with acute ischemic stroke diagnosed and treated in our hospital from June 2020 to June 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 34 cases in each group. The control group was treated with clopidogrel combined with aspirin, and the observation group was treated with atorvastatin on the basis of the control group. The neurological deficits, daily living ability, coagulation function indexes [prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fg)], blood lipid indexes [cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)], incidence of adverse reactions and prognosis were compared between the two groups.Results After treatment, the NIHSS score of the two groups was lower than that before treatment, the Barthel score was higher than that before treatment, and the NIHSS score of the observation group was lower than that of the control group, and the Barthel score was higher than that of the control group (P<0.05). After treatment, PT and APTT in the two groups were greater than those before treatment, Fg was less than that before treatment, and PT and APTT in the observation group were greater than those in the control group, Fg was less than that in the control group (P<0.05). After treatment, TC and LDL-C in the two groups were lower than those before treatment, HDL-C was higher than that before treatment, and TC and LDL-C in the observation group were lower than those in the control group, HDL-C was higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). The recurrence rate and bleeding rate of the observation group were lower than those of the control group (P<0.05).Conclusion Atorvastatin combined with dual antiplatelet therapy has a positive effect on blood lipids, neurological function and prognosis in patients with acute ischemic stroke, and does not increase the incidence of adverse reactions. It is a safe and effective treatment.

参考文献/References:

[1]曹妍.急性缺血性小卒中在CISS病因分型中的危险因素分析及其双抗血小板干预后的疗效观察[D].石家庄:河北医科大学,2016.[2]崔接门.双抗和单抗治疗急性非心源性轻中度缺血性脑卒中的随机、平行对照研究[D].大连:大连医科大学,2017.[3]郭小双,尹泽刚,严冬梅.双联抗血小板联合不同剂量阿托伐他汀钙对急性脑梗塞患者血清MCP-1、VE-cadherin水平的影响[J].心血管康复医学杂志,2019,28(4):450-454.[4]彭敏.小剂量氯吡格雷联合阿司匹林用于75岁以上急性脑梗死患者的疗效及安全性评价[J].中国药业,2016,25(11):55-57.[5]Lv G,Wang GQ,Xia ZX,et al.Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients[J].Mil Med Res,2019,6(1):2.[6]赵义纯,任扬,李乐军.瑞舒伐他汀钙与阿托伐他汀钙治疗急性脑梗死血脂及炎症反应指标比较[J]. 贵州医药,2018,42(12):1476-1478.[7]袁定新,邓燕华,骆晓敏,等.双联与单用抗血小板在缺血性脑卒中急性期应用的对照研究[J].中国实用神经疾病杂志,2017,20(20):46-49.[8]崔莹莹,朱之悦,董重.阿普替酶静脉溶栓治疗对急性缺血性脑卒中患者凝血功能及炎性因子的影响观察[J].吉林医学,2021,42(10):2457-2459.[9]韩云鹏,杨立臣,张琳琳.常规MRI、SWI联合第3代双源CT早期鉴别诊断急性缺血性脑卒中血管内治疗后出血灶与碘对比剂外渗的临床价值[J].中西医结合心脑血管病杂志,2022,20(15):2861-2864. [10]张银善,张敏,赵志英,等.阿托伐他汀辅助治疗急性缺血性脑卒中对循环内皮祖细胞及神经功能的影响[J].现代中西医结合杂志,2017,26(28):3131-3133.[11]蒋慧.氯吡格雷对急性缺血性脑卒中患者疗效及血清炎性标记物的影响效果分析[J].贵州医药,2016,40(8):828-830.[12]石蕊.阿托伐他汀联合氯吡格雷+阿司匹林双抗治疗对缺血性急性脑卒中患者再发血管事件的获益及风险分析[J].湖南师范大学学报(医学版),2018,15(1):104-107.[13]周薇,罗飞,王浩.阿托伐他汀对急性缺血性脑卒中患者外周血VEGF及SDF-1的影响[J].临床和实验医学杂志,2017,16(17):1710-1713.[14]刘胜武,郭改艳,吴瑞,等.阿托伐他汀治疗急性缺血性脑卒中的随机对照试验研究[J].延安大学学报(医学科学版),2017,15(3):11-13,17.[15]张成刚,孙中武.阿托伐他汀钙联合氯吡格雷预防老年短暂性脑缺血发作患者脑梗死的效果及对血脂、血小板的影响[J].中国老年学杂志,2016,36(19):4759-4760.[16]左凤同,董爱勤,刘辉,等.阿司匹林联合硫酸氯吡格雷及阿托伐他汀对伴有脑血管狭窄的老年缺血性脑血管病患者的二级预防[J].中国老年学杂志,2016,36(10):2396-2398.[17]任艳丽,郭文彬.阿托伐他汀联合前列地尔治疗老年急性缺血性脑卒中伴颅内动脉狭窄的效果[J]. 河南医学研究,2021,30(2):296-298.[18]徐庆兵,房晓莉,童海涛.阿托伐他汀治疗急性缺血性脑卒中患者早期神经功能恶化和短期转归的最佳剂量研究[J].实用临床医药杂志,2017,21(15):10-13.[19]韦朝霞,潘速跃,祁风,等.他汀类药物治疗对急性缺血性脑卒中预后的影响[J].中华行为医学与脑科学杂志,2016,25(5):476-480.

相似文献/References:

[1]王跃慧.急性缺血性脑卒中的药物治疗[J].医学信息,2022,35(11):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
　WANG Yue-hui.Drug Treatment of Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(23):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
[2]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Journal of Medical Information,2022,35(23):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
[3]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(23):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[4]王润俊.阿托伐他汀改善蛛网膜下腔出血患者的预后分析[J].医学信息,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
　WANG Run-jun.Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage[J].Journal of Medical Information,2018,31(23):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
[5]袁 敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对 血小板参数的影响[J].医学信息,2018,31(16):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
　YUAN Min,ZHOU Yuan-cheng.Effect of Atorvastatin Combined with Antiplatelet Drugs on Patients with Cerebral Thrombosis and its Influence on Platelet Parameters[J].Journal of Medical Information,2018,31(23):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
[6]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Journal of Medical Information,2019,32(23):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[7]沈有录,卢红涛,刘维军.阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响[J].医学信息,2019,32(06):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
　SHEN You-lu,LU Hong-tao,LIU Wei-jun.Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI[J].Journal of Medical Information,2019,32(23):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
[8]王珊珊.国内丁苯肽治疗急性缺血性脑卒中机制的应用研究[J].医学信息,2019,32(09):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
　WANG Shan-shan.Study on the Application of Domestic Butyl Phenyl Peptide in the Treatment of Acute Ischemic Stroke[J].Journal of Medical Information,2019,32(23):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
[9]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Journal of Medical Information,2019,32(23):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[10]郑钰蓉,殷 梅,罗 悯.急性缺血性脑卒中伴发脑心综合征的临床研究[J].医学信息,2022,35(17):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]
　ZHENG Yu-rong,YIN Mei,LUO Min.Clinical Study of Acute Ischemic Stroke with Cerebrocardiac Syndrome[J].Journal of Medical Information,2022,35(23):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]

更新日期/Last Update: 1900-01-01